Search results
RSV Infection Raises Risk for Acute Cardiovascular Events
Medscape· 19 hours agoAccording to a US cross-sectional study, every fifth hospital patient with a respiratory syncytial ...
Electronic Health Record–Based Algorithm for Monitoring Respiratory Virus–Like Illness
Centers for Disease Control and Prevention· 14 hours agoIllness and death associated with seasonal respiratory syncytial virus (RSV) spikes, the SARS-CoV-2 pandemic, and occasional clusters of infection from ...
HSA approves new RSV vaccine – a breakthrough in elderly respiratory health
MSN News· 22 hours agoSINGAPORE: Singapore’s Health Sciences Administration (HSA) has given the green light to the Arexvy...
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 2 days agoModerna stock tumbled — and then rebounded — after the Food and Drug Administration delayed its RSV...
Does Medicare Cover the RSV Vaccine?
US News Health· 2 days agoCDC recommends vaccination for higher-risk populations. Two vaccines – Arexvy and Abrysvo – are currently approved by the FDA for those ages 60 and older and offers protection for two years.
Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
Morningstar· 7 days agoModerna on Friday said the Food and Drug Administration won't meet its May 12 target action date for a decision on the company's proposed vaccine for respiratory syncytial virus< ...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks via Yahoo Finance· 3 days agoShares of Moderna, Inc. MRNA were down 4.4% on May 10 after the company announced that the FDA has...
NanoViricides CEO discusses NV-387’s broad-spectrum antiviral potential
Proactive Investors· 3 days agoNanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad...
Moderna says FDA delayed RSV vaccine approval to end of May
CNBC· 7 days agoModerna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for...
Is This a Setback for Moderna?
The Motley Fool via AOL· 3 days agoInvestors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it...